AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26133379 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive follow-up investigations via registry offices and cancer registry.
Number of subjects: 2000
Study 26133547 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155 U every 12 weeks for 9 cycles)
Number of subjects: 500
Study 26133547 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 500
Study 26133566 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg of ceftazidime + 500 mg of avibactam
Number of subjects: 43
Study 26133566 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg of ceftazidime + 1000 mg of avibactam
Number of subjects: 43
Study 26133811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (100-800 mg/day)
Number of subjects: 376
Study 26133904 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 329
Study 26133904 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 329
Study 26133904 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from CCE
Number of subjects: 329
Study 26133904 — intervention group
Group type: COMPARATOR
Intervention: Crossover from Colonoscopy
Number of subjects: 329
Study 26134834 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive insulin delivery setting
Number of subjects: 12
Study 26134834 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium insulin delivery setting
Number of subjects: 12
Study 26134834 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative insulin delivery setting
Number of subjects: 12
Study 26134834 — intervention group
Group type: EXPERIMENTAL
Intervention: Most aggressive setting
Number of subjects: 12
Study 26134834 — intervention group
Group type: COMPARATOR
Intervention: All aggressiveness settings
Number of subjects: 12
Study 26135098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate (SPMC)
Number of subjects: 368
Study 26135098 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-based electrolyte solutions (PEG-ELS)
Number of subjects: 368
Study 26135344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-cm larger waist circumference (WC) adjusted for BMI
Number of subjects: 1024
Study 26135344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-unit higher body mass index (BMI) adjusted for WC
Number of subjects: 1024
Study 26135681 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 resection margin
Number of subjects: 2815
Study 26135681 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy in R1 patients
Number of subjects: 2815
Study 26135681 — intervention group
Group type: COMPARATOR
Intervention: R0 resection margin
Number of subjects: 2815
Study 26135770 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ischemia-modified albumin (IMA) concentrations in women with early pregnancy loss
Number of subjects: 180
Study 26135770 — intervention group
Group type: COMPARATOR
Intervention: Serum ischemia-modified albumin (IMA) concentrations in healthy pregnant women
Number of subjects: 180
Study 26135770 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of IMA >163 ng/mL
Number of subjects: 180
Study 26136164 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F]HX4 PET imaging
Number of subjects: 19
Study 26136476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemrix vaccination
Number of subjects: 0
Study 26136476 — intervention group
Group type: COMPARATOR
Intervention: Focetria vaccination
Number of subjects: 0
Study 26136476 — intervention group
Group type: COMPARATOR
Intervention: 2009 A(H1N1) pandemic influenza infection
Number of subjects: 0
Study 26137304 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/day vitamin D supplementation
Number of subjects: 27
Study 26137304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 26137304 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D ≥ 75 nmol/L
Number of subjects: 27
Study 26137355 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 0
Study 26137355 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 mg/d
Number of subjects: 0
Study 26137355 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 400 mg/d
Number of subjects: 0
Study 26137355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26137358 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 25 mg/d for 1 week followed by placebo for 3 weeks (taper)
Number of subjects: 357
Study 26137358 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks (abrupt discontinuation)
Number of subjects: 357
Study 26137358 — intervention group
Group type: COMPARATOR
Intervention: Desvenlafaxine 50 mg/d for 4 weeks (no discontinuation)
Number of subjects: 357
Study 26137532 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, sertraline or venlafaxine-ER for 8 weeks
Number of subjects: 157
Study 26137532 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI volumetric and connectivity measures
Number of subjects: 157
Study 26137953 — intervention group
Group type: EXPERIMENTAL
Intervention: TC/HDL-C
Number of subjects: 1310432
Study 26137953 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, sex, and directly measured components of the standard lipid profile
Number of subjects: 1310432
Study 26137961 — intervention group
Group type: EXPERIMENTAL
Intervention: CD200/BTLA deletions
Number of subjects: 1154
Study 26137961 — intervention group
Group type: COMPARATOR
Intervention: Non-deleted cases
Number of subjects: 1154
Study 26137969 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 65
Study 26137969 — intervention group
Group type: EXPERIMENTAL
Intervention: State Entropy (SE)
Number of subjects: 65
Study 26137969 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS and SE
Number of subjects: 65
Study 26137971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and metronidazole followed by vaginal EcoVag® capsules for 5 consecutive days after each antibiotic treatment.
Number of subjects: 40
Study 26137971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and metronidazole treatment together with prolonged administration of EcoVag® (10 consecutive days after each antibiotic treatment followed by weekly administration for next four months).
Number of subjects: 40
Study 26137971 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended fluconazole and EcoVag® treatment.
Number of subjects: 40
Study 26137971 — intervention group
Group type: COMPARATOR
Intervention: Extended fluconazole treatments only.
Number of subjects: 40
Study 26137971 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of isolation of any Lactobacillus species during the study.
Number of subjects: 40
Study 26137971 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of isolation of EcoVag® strains.
Number of subjects: 40
Study 26137971 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in sexual partner.
Number of subjects: 40
Study 26137973 — intervention group
Group type: COMPARATOR
Intervention: Masked angry faces
Number of subjects: 37
Study 26137973 — intervention group
Group type: COMPARATOR
Intervention: Unmasked angry faces
Number of subjects: 37
Study 26137973 — intervention group
Group type: COMPARATOR
Intervention: Masked happy faces
Number of subjects: 37
Study 26137973 — intervention group
Group type: COMPARATOR
Intervention: Unmasked happy faces
Number of subjects: 37
Study 26137973 — intervention group
Group type: COMPARATOR
Intervention: Masked face processing across emotions
Number of subjects: 37
Study 26138124 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26138630 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation (AF) during ARDS
Number of subjects: 282
Study 26138630 — intervention group
Group type: COMPARATOR
Intervention: No new-onset atrial fibrillation (AF) during ARDS
Number of subjects: 282
Study 26138702 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain crispbread low-fructose, low-calorie diet (CB-LCD)
Number of subjects: 51
Study 26138702 — intervention group
Group type: COMPARATOR
Intervention: Traditional low-calorie diet based on fructose-rich liquid meal replacements (LMR-LCD)
Number of subjects: 51
Study 26138923 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with a positive family history of dementia
Number of subjects: 576
Study 26138923 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular dementia (VaD)
Number of subjects: 576
Study 26138923 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 576
Study 26138923 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontotemporal dementia (FTD)
Number of subjects: 576
Study 26138923 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtypes of dementia
Number of subjects: 576
Study 26138923 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of dementia
Number of subjects: 576
Study 26138923 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 576
Study 26139558 — intervention group
Group type: EXPERIMENTAL
Intervention: MABp1 (1.25mg/kg body weight, four biweekly intravenous infusions)
Number of subjects: 7
Study 26140502 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (n = 40)
Number of subjects: 212
Study 26140502 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) (n = 152)
Number of subjects: 212
Study 26140502 — intervention group
Group type: COMPARATOR
Intervention: Treatment crossover (n = 20)
Number of subjects: 212
Study 26141008 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI ≥30)
Number of subjects: 825
Study 26141008 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 825
Study 26141008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender, depression score, and BMI
Number of subjects: 825
Study 26141371 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 60
Study 26141371 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 60
Study 26141371 — intervention group
Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 60
Study 26141371 — intervention group
Group type: COMPARATOR
Intervention: Operated legs
Number of subjects: 60
Study 26141713 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility preservation counseling and information provided to patients and parents
Number of subjects: 290
Study 26141713 — intervention group
Group type: COMPARATOR
Intervention: Pressure from doctors to reduce the delay between diagnosis and cancer treatment
Number of subjects: 290
Study 26141713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hope for future parenthood
Number of subjects: 290
Study 26141713 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support
Number of subjects: 290
Study 26141713 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical support
Number of subjects: 290
Study 26142620 — intervention group
Group type: EXPERIMENTAL
Intervention: Home use of mifepristone
Number of subjects: 400
Study 26142620 — intervention group
Group type: COMPARATOR
Intervention: Center use of mifepristone
Number of subjects: 400
Study 26143178 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported (SR) data via the internet
Number of subjects: 140
Study 26143178 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported (SR) weight
Number of subjects: 140
Study 26143178 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported (SR) BMI
Number of subjects: 140
Study 26143178 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI classification
Number of subjects: 140
Study 26143178 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric data (height, weight, BMI)
Number of subjects: 140
Study 26143178 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype information
Number of subjects: 140
Study 26143178 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic data (age and sex verification)
Number of subjects: 140
Study 26143264 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma GVAX (5E7 cells/cycle, 2E8 cells/cycle, or 2E8 cells/cycle with cyclophosphamide 200 mg/m2) administered intradermally once every 28 days for four cycles
Number of subjects: 20
Study 26143264 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma GVAX
Number of subjects: 20
Study 26143343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Sildenafil
Number of subjects: 2
Study 26146564 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative percent method (HRR group)
Number of subjects: 42
Study 26146564 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold based method (ACE-3ZM)
Number of subjects: 42
Study 26146564 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 42
Study 26147770 — intervention group
Group type: EXPERIMENTAL
Intervention: S-TOFHLA
Number of subjects: 402
Study 26147770 — intervention group
Group type: EXPERIMENTAL
Intervention: NVS
Number of subjects: 402
Study 26147770 — intervention group
Group type: EXPERIMENTAL
Intervention: S-TOFHLA (Spanish)
Number of subjects: 402
Study 26147770 — intervention group
Group type: EXPERIMENTAL
Intervention: NVS (Spanish)
Number of subjects: 402
Study 26147770 — intervention group
Group type: EXPERIMENTAL
Intervention: S-TOFHLA (English)
Number of subjects: 402
Study 26148006 — intervention group
Group type: EXPERIMENTAL
Intervention: CLI patients not using aspirin
Number of subjects: 20
Study 26148006 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal reactivity to stimulation of collagen and thrombin activation pathway in CLI patients
Number of subjects: 20
Study 26148006 — intervention group
Group type: EXPERIMENTAL
Intervention: CLI patients
Number of subjects: 20
Study 26148006 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactivity of platelets in CLI patients
Number of subjects: 20
Study 26148006 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 26148170 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 0
Study 26148170 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 0
Study 26148518 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative management with drains maintained for 7 days and bilirubin measured on postoperative days 3, 5, and 7.
Number of subjects: 475
Study 26148518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle maneuvers lasting ≥90 min.
Number of subjects: 475
Study 26148518 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended resections.
Number of subjects: 475
Study 26148518 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions.
Number of subjects: 475
Study 26148518 — intervention group
Group type: EXPERIMENTAL
Intervention: Resections including segment I.
Number of subjects: 475
Study 26148518 — intervention group
Group type: EXPERIMENTAL
Intervention: Resections including segment V.
Number of subjects: 475
Study 26148518 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis on POD 7.
Number of subjects: 475
Study 26148750 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg orally 3 times/day) + Whole-Brain Radiotherapy (WBRT, 3.0 Gy per day, 5 days per week, to 30 Gy)
Number of subjects: 20
Study 26148750 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib + WBRT
Number of subjects: 20
Study 26148819 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter defibrillator (S-ICD) system
Number of subjects: 55
Study 26149529 — intervention group
Group type: EXPERIMENTAL
Intervention: VTV (viable tumor volume) criteria
Number of subjects: 17
Study 26149529 — intervention group
Group type: COMPARATOR
Intervention: RECIST 1.1 response
Number of subjects: 17
Study 26149529 — intervention group
Group type: COMPARATOR
Intervention: MASS criteria
Number of subjects: 17
Study 26149529 — intervention group
Group type: COMPARATOR
Intervention: Choi criteria
Number of subjects: 17
Study 26149529 — intervention group
Group type: COMPARATOR
Intervention: Volumetric measurements
Number of subjects: 17
Study 26149600 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine 20 mL injected bilaterally into the fascial plane between the multifidus and longissimus muscles
Number of subjects: 10
Study 26150440 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14 after two cycles
Number of subjects: 138
Study 26150440 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14 after two cycles with central review
Number of subjects: 138
Study 26150440 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14 at end of treatment with central review
Number of subjects: 138
Study 26151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery with 8-second freeze time
Number of subjects: 8
Study 26151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery with 12-second freeze time
Number of subjects: 8
Study 26151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery with freeze-times greater than 5 seconds
Number of subjects: 8
Study 26151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery with freeze-times greater than 8 seconds
Number of subjects: 8
Study 26151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological analysis of blister roofs
Number of subjects: 8
Study 26152123 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor activity intervention (two additional 20-min recess programs outside the classroom)
Number of subjects: 3051
Study 26152123 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor activity intervention
Number of subjects: 3051
Study 26152560 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Contact Force (CF) ≥10 g
Number of subjects: 30
Study 26152560 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing CF at a location where initial CF was <10 g and CF increased ≥4.5 g in sinus rhythm or ≥8 g in atrial fibrillation
Number of subjects: 30
Study 26152560 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter orientation changed from perpendicular to parallel in atrial fibrillation
Number of subjects: 30
Study 26152560 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing CF at a location with initial CF <10 g and CF increased ≥8 g
Number of subjects: 30
Study 26152560 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CF
Number of subjects: 30
Study 26152560 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial CF ≥10 g
Number of subjects: 30
Study 26153272 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein, soluble E-selectin, and soluble intercellular adhesion molecule-1 in type 2 diabetes
Number of subjects: 136
Study 26153272 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18 in type 1 diabetes
Number of subjects: 136
Study 26153272 — intervention group
Group type: EXPERIMENTAL
Intervention: sE-selectin in type 2 diabetes
Number of subjects: 136
Study 26153510 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban)
Number of subjects: 200
Study 26153510 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 200
Study 26153531 — intervention group
Group type: EXPERIMENTAL
Intervention: LES-EST
Number of subjects: 44
Study 26153726 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin augmentation therapy
Number of subjects: 0
Study 26153726 — intervention group
Group type: COMPARATOR
Intervention: Matched PiZZ individuals not on augmentation therapy
Number of subjects: 0
Study 26153726 — intervention group
Group type: COMPARATOR
Intervention: PiMZ participants not on augmentation therapy
Number of subjects: 0
Study 26153726 — intervention group
Group type: COMPARATOR
Intervention: Control participants from the Subpopulations and Intermediate Outcome Measures in COPD Study
Number of subjects: 0
Study 26154653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lap-Band AP implantation (post-LBAP)
Number of subjects: 585
Study 26155776 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble EPCR variant (E86A-sEPCR)
Number of subjects: 0
Study 26155776 — intervention group
Group type: COMPARATOR
Intervention: CIDRα1.1 domain of PfEMP1
Number of subjects: 0
Study 26155941 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 208 (oral MET inhibitor)
Number of subjects: 54
Study 26155957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low albuminuria (LA, 10-29 mg/24 h)
Number of subjects: 11538
Study 26155957 — intervention group
Group type: COMPARATOR
Intervention: Normal albuminuria (NA, <10 mg/24 h)
Number of subjects: 11538
Study 26155957 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of anti-hyperglycaemic and anti-hypertensive agents
Number of subjects: 11538
Study 26155994 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 93
Study 26156015 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-TTE (A4C view)
Number of subjects: 282
Study 26156015 — intervention group
Group type: COMPARATOR
Intervention: 3D-transesophageal echocardiography
Number of subjects: 282
Study 26156015 — intervention group
Group type: COMPARATOR
Intervention: 2D-TTE (surgical measurements)
Number of subjects: 282
Study 26156015 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (A4C view)
Number of subjects: 282
Study 26156652 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemoradiotherapy (60 Gy in 30 fractions to tumour, 50 Gy in 30 fractions to elective lymph node volumes, 5 Gy endorectal brachytherapy boost, and oral tegafur-uracil 300 mg/m(2) every weekday for 6 weeks)
Number of subjects: 55
Study 26156652 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation (watchful waiting) after chemoradiotherapy
Number of subjects: 55
Study 26156652 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemoradiotherapy
Number of subjects: 55
Study 26156741 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 59
Study 26156741 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous adipose tissue (SAT)
Number of subjects: 59
Study 26156741 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum metabolites
Number of subjects: 59
Study 26156741 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue gene expression
Number of subjects: 59
Study 26156945 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric ring annuloplasty
Number of subjects: 65